Following four doses of MAGE-A3 immunotherapeutic, MAGE-A3-specific antibody response was observed in all patients, and all patients were seropositive, which is consistent with the results of previous studies with MAGE-A3 immunotherapeutic in melanoma or NSCLC.15 18 20. The gene discussed is MAGEA3; the disease is melanoma.